Progressive renal insufficiency related to ALK inhibitor, alectinib

Alectinib is a second generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor and is generally effective and tolerated in patients who have demonstrated disease progression or adverse effects while on the first generation inhibitor, crizotinib. ALK inhibitors can cause a reversible chr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oxf Med Case Reports
Hauptverfasser: Nagai, Kojiro, Ono, Hiroyuki, Matsuura, Motokazu, Hann, Michael, Ueda, Sayo, Yoshimoto, Sakiya, Tamaki, Masanori, Murakami, Taichi, Abe, Hideharu, Ishikura, Hisashi, Doi, Toshio
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2018
Schlagworte:
Case Report
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5915949/
https://ncbi.nlm.nih.gov/pubmed/29713488
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/omcr/omy009
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge